Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug bimekizumab shows promise in clearing psoriasis in phase 3 trial

NCT ID NCT03410992

Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 study tested bimekizumab, a drug given by injection, against a placebo in 435 adults with moderate to severe plaque psoriasis. The main goal was to see how many people achieved at least 90% skin clearing after 16 weeks. The trial also looked at complete clearing and overall improvement. Results could support bimekizumab as a new treatment option for psoriasis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bimekizumab
What this could lead to
If successful, bimekizumab could offer a new treatment option for people with moderate to severe plaque psoriasis, helping clear skin more effectively.
What could go wrong
This is a single phase 3 trial; results need confirmation. Bimekizumab may not work for everyone and could have side effects like any biologic drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

435 people

The number who actually took part.

Started

Feb 2018

Finished

Jan 2020

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Must be at least 18 years of age * Chronic plaque psoriasis (PSO) for at least 6 months prior to the Screening Visit * Psoriasis Area Severity Index (PASI) \>=12 and body surface area (BSA) affected by PSO \>=10% and Investigator's Global Assessment (IGA) score \>=3 on a 5-point scale * Subject is a candidate for systemic PSO therapy and/or phototherapy * Female subject of child bearing potential must be willing to use highly effective method of contraception Exclusion Criteria: * Subject has an active infection (except common cold), a recent serious infection, or a history of opportunistic, recurrent, or chronic infections * Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection * Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection * Subject has any other condition, including medical or psychiatric, which, in the Investigator's judgment, would make the subject unsuitable for inclusion in the study * Presence of active suicidal ideation or positive suicide behavior * Presence of moderately severe major depression or severe major depression * Subject has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic plaque psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic plaque psoriasis Moderate-to-severe chronic plaque psoriasis Psoriatic arthritis

Contacts and locations

Locations

  • Ps0013 003

    Carlton, Australia

  • Ps0013 006

    Kogarah, Australia

  • Ps0013 008

    East Melbourne, Australia

  • Ps0013 200

    Schwerin, Germany

  • Ps0013 202

    Hamburg, Germany

  • Ps0013 204

    Witten, Germany

  • Ps0013 219

    Münster, Germany

  • Ps0013 220

    Hamburg, Germany

  • Ps0013 250

    Szolnok, Hungary

  • Ps0013 253

    Orosháza, Hungary

  • Ps0013 258

    Veszprém, Hungary

  • Ps0013 260

    Szeged, Hungary

  • Ps0013 261

    Budapest, Hungary

  • Ps0013 262

    Miskolc, Hungary

  • Ps0013 350

    Warsaw, Poland

  • Ps0013 351

    Warsaw, Poland

  • Ps0013 352

    Gdansk, Poland

  • Ps0013 353

    Szczecin, Poland

  • Ps0013 354

    Warsaw, Poland

  • Ps0013 355

    Bialystok, Poland

  • Ps0013 356

    Lublin, Poland

  • Ps0013 357

    Kielce, Poland

  • Ps0013 358

    Katowice, Poland

  • Ps0013 359

    Katowice, Poland

  • Ps0013 360

    Lodz, Poland

  • Ps0013 361

    Bialystok, Poland

  • Ps0013 363

    Krakow, Poland

  • Ps0013 365

    Wroclaw, Poland

  • Ps0013 366

    Katowice, Poland

  • Ps0013 368

    Wroclaw, Poland

  • Ps0013 369

    Bialystok, Poland

  • Ps0013 370

    Wroclaw, Poland

  • Ps0013 374

    Poznan, Poland

  • Ps0013 400

    Moscow, Russia

  • Ps0013 401

    Saratov, Russia

  • Ps0013 402

    Moscow, Russia

  • Ps0013 403

    Moscow, Russia

  • Ps0013 404

    Saint Petersburg, Russia

  • Ps0013 405

    Saint Petersburg, Russia

  • Ps0013 406

    Yaroslavl, Russia

  • Ps0013 550

    Manchester, United Kingdom

  • Ps0013 554

    Reading, United Kingdom

  • Ps0013 555

    Salford, United Kingdom

  • Ps0013 657

    Waterloo, Canada

  • Ps0013 658

    Ajax, Canada

  • Ps0013 660

    Montreal, Canada

  • Ps0013 663

    Mississauga, Canada

  • Ps0013 665

    Québec, Canada

  • Ps0013 667

    Ottawa, Canada

  • Ps0013 668

    North Bay, Canada

  • Ps0013 671

    Hamilton, Canada

  • Ps0013 672

    Edmonton, Canada

  • Ps0013 675

    Markham, Canada

  • Ps0013 676

    Surrey, Canada

  • Ps0013 701

    Busan, South Korea

  • Ps0013 703

    Seoul, South Korea

  • Ps0013 705

    Seongnam-si, South Korea

  • Ps0013 901

    Portsmouth, New Hampshire, 03801, United States

  • Ps0013 914

    San Antonio, Texas, 78213, United States

  • Ps0013 919

    San Diego, California, 92103, United States

  • Ps0013 928

    Fort Myers, Florida, 33912, United States

  • Ps0013 929

    Portland, Oregon, 97223, United States

  • Ps0013 933

    Murray, Utah, 84107, United States

  • Ps0013 937

    Johnston, Rhode Island, 02919, United States

  • Ps0013 940

    Beverly, Massachusetts, 01915, United States

  • Ps0013 944

    New Orleans, Louisiana, 70115, United States

  • Ps0013 947

    Buffalo, New York, 14221, United States

  • Ps0013 949

    Cleveland, Ohio, 44106-1716, United States

  • Ps0013 954

    Skokie, Illinois, 60077, United States

  • Ps0013 955

    San Diego, California, 92123, United States

  • Ps0013 956

    Verona, New Jersey, 07044-2946, United States

  • Ps0013 962

    Owensboro, Kentucky, 42303, United States

  • Ps0013 963

    Rochester, New York, 14623, United States

  • Ps0013 965

    New York, New York, 10025, United States

  • Ps0013 966

    Sandy Springs, Georgia, 30329, United States

  • Ps0013 967

    Santa Monica, California, 90404, United States

  • Ps0013 968

    New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.